Corporate Presentation Corporate Presentation Partnering Healthcare Globally Partnering Healthcare Globally July July 11 11 Ipca Laboratories Limited
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 1/48
Corporate PresentationCorporate Presentation
Partnering Healthcare Globally Partnering Healthcare Globally
July July ’’ 1111
Ipca Laboratories Limited
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 2/48
Company Overview
Fully integrated Pharmaceuticalcompany producing Branded &
Generics Formulations, APIs &Intermediates.
Business Model
Over 8,900Number of Employees
Rs. 10,252 Mn.USD 225 Mn.
Exports F.Y. 2010-11
Rs. 18,895 Mn.USD 415 Mn.Total Income F.Y. 2010-11
1975Present Management since
1949Incorporation
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 3/48
UK - MHRA, US - FDA.TGA-Australia, HPB Canada
Tablets &Capsules
Silvassa
UK- MHRA,MCC – South Africa,
Betalactum –Tablets, Capsules& Dry Syrups.
Kandla (Gujarat)
MCC-S.AfricaTablets, Liquids &Injectables
Ratlam(Madhya Pradesh)
UK-MHRA, TGA-Australia,MCC-South Africa, HPBCanada, WHO-Geneva
Tablets &Capsules
Athal (Silvassa)
Approvals / InspectionsDosage FormLocation
FormulationsFormulations
Manufacturing FacilitiesManufacturing Facilities
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 4/48
UK – MHRATablets & CapsulesIndore (SEZ)(MadhyaPradesh)
WHO - GMPTablets & Cephalosporin
Injectables
Dehradun
(Uttaranchal)
Approvals / InspectionsDosage FormLocation
FormulationsFormulations
Manufacturing FacilitiesManufacturing Facilities
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 5/48
WHO - GMPAurangabad (Maharashtra)
WHO - GMPIndore(Madhya Pradesh)
US – FDA ,TGA – AustraliaEDQM, Danish Regulatory Authority,
PMDA-Japan, WHO-Geneva
Ratlam(Madhya Pradesh)
Approvals / InspectionsLocation
Active Pharmaceutical Ingredients (APIs)Active Pharmaceutical Ingredients (APIs)
Manufacturing FacilitiesManufacturing Facilities
The company has taken effective steps for setting up a new greenThe company has taken effective steps for setting up a new greenThe company has taken effective steps for setting up a new greenThe company has taken effective steps for setting up a new greenfield API manufacturing facility atfield API manufacturing facility atfield API manufacturing facility atfield API manufacturing facility at VadodaraVadodaraVadodaraVadodara (Gujarat)(Gujarat)(Gujarat)(Gujarat)
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 6/48
-Dosage Form –Tablets &Capsules
Sikkim
Approvals / Inspections
Dosage Form / CapacityLocation
Projects Under ImplementationProjects Under Implementation
Manufacturing FacilitiesManufacturing Facilities
Sikkim formulations manufacturing Plant started commercialSikkim formulations manufacturing Plant started commercialSikkim formulations manufacturing Plant started commercialSikkim formulations manufacturing Plant started commercialProduction in July 2011.Production in July 2011.Production in July 2011.Production in July 2011.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 7/48
Revenue Break-up (2010-11)
Formulations 74% APIs 26% Domestic 46%Exports 54%
Formulations 67% APIs 33%
T o
t a l R e v e n u e
B r e a
k u p
T o
t a l R e v e n u e
B r e a
k u p
E x p o r t s
B r e a
k u p
D o m e s
t i c B r e a
k u p
Formulations 83% APIs 17%
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 8/48
Revenue Break-upRs. Mn. Domestic Exports Total Domestic Exports Total
BrandedFormulations 6964 1558 8522 5898 1298 7196 18.4%
GenericFormulations 5359 5359 80 3594 3674 45.9%
TotalFormulations 6964 6917 13881 5978 4892 10870 27.7%
API /Intermediates 1443 3335 4778 1416 3169 4585 4.2%
Others 236 236 200 200
Total Income 8643 10252 18895 7594 8061 15655 20.7%
Growth 13.7% 27.2% 20.7%
2010-11 2009-10 Growth
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 9/48
Financials
(Rs. Mn.) USD (Mn.) (Rs. Mn.) USD (Mn.) % Growth
Total Income 18895 415 15655 343 20.7%
EBIDT 3785 83 3319 73 14.0%
EBIDT % 20.12% 21.37%PBT # 3437 75 2717 60 26.5%
PBT % 18.27% 17.50%
PAT # 2554 56 2092 46 22.1%PAT % 13.58% 13.47%
FY 2010-11 FY 2009-10
# After forex gain of Rs.433Mn as against forex gain of Rs.58Mn for previous year.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 10/48
Financials
Profitability to Net Income FY 2010-2011 FY 2009-2010 FY 2008-2009
PBIDT 20.12% 21.37% 21.03%
PBT 18.27% 17.50% 9.79%PAT (before exceptional items) 14.11% 13.47% 7.96%
Net Profit (after exceptional items) 13.58% 13.47% 7.16%
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 11/48
FinancialsBusiness Characteristics FY 2010-2011 FY 2009-2010 FY 2008-2009
Return on Capital Employed %
(PBIT/Capital Employed) 26.14% 24.82% 16.35%Return on Net Worth % (PAT/NetWorth) 25.18% 23.91% 15.88%
Fixed Asset Turnover Ratio (TotalIncome/Net Fixed Assets) 2.33 2.32 2.20
Capital Employed Turnover Ratio(Total Income/ Capital Employed) 1.35 1.33 1.36
Asset Coverage Ratio (to term loan)(Net Fixed Assets/Long Term Loans) 3.04 3.07 2.51Long Term Debt Equity Ratio (Long
Term Loan/ NetWorth) 0.25 0.25 0.36Debtors Turnover Ratio (Days)(Debtors/ Turnover)x365 91 93 99Creditors Turnover Ratio (Days)(Creditors/ Purchases)x365 56 60 62Inventory Turnover Ratio (Days)
(Inventory/ Turnover)x365 90 88 86
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 12/48
Financials
Growth FY 2010-2011 FY 2009-2010 FY 2008-2009
Total Income 20.7% 22.7% 20.4%
Domestic Sales 13.7% 26.4% 15.6%
Export Sales 27.2% 18.5% 26.9%
PBIDT 14.0% 23.9% 45.8%
PBT 26.5% 118.0% -29.5%
PAT (before exceptional items) 26.8% 106.3% -28.1%
Net Profit (after exceptional items) 22.1% 129.3% -35.4%
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 13/48
Financials
(Rs. Mn.) USD (Mn.) (Rs. Mn.) USD (Mn.) % Growth
Total Income 5326 117 4205 92 26.7%
EBIDT 952 21 712 16 33.7%
EBIDT % 17.96% 17.04%
PBT # 832 18 511 11 62.8%
PBT % 15.62% 12.15%
PAT # 617 14 388 9 59.0%
PAT % 11.58% 9.22%
Q1 2011-12 Q1 2010-11
# After forex gain of Rs.91Mn as against forex loss of Rs.29Mn for previous year.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 14/48
Contribution of Therapeutic GroupsGroups
1%-Nutraceuticals--
100%100%Total100%100%
1%4%Others1%8%
4%-Dermatology4%-4%1%Cough Preparations4%1%
4%3%Neuro psychiatry4%1%
6%1%Gastro-intestinal (GI) products7%2%
8%11%Anti-bacterials9%19%17%19%Anti-malarials17%7%
28%20%Non steroidal anti-inflammatory drugs(NSAID)26%21%
27%41%Cardiovasculars & Anti-diabetics28%41%
DomesticExportsTherapeutic SegmentDomesticExports
2010-112009-10
Revenue Break-up (Formulations)
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 15/48
Branded Formulations – Domestic
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 16/48
Formulations Business - Domestic
All India Rank ORG-IMS : 26th (MAT June’11).
23 Depots & 2 C&F agents.
13 Therapy Focused Marketing Divisions including 2 newdivisions - Ipca Pain Management & Ipca Dynamix.
Field Strength - 5400
1500 Wholesalers.
4 brands among top 300 brands (HCQS, Lariago, Perinorm &Rapither)Market leaders in Anti-malarials & Rheumatoid Arthritis.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 17/48
95
105
131153
2007-08 2008-09 2009-10 2010-11
Formulations Business - Domestic
Sales Rs.Mn .Sales USD Mn.CAGR = 17%
4766
4319
5978 6964
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 18/48
New Product SalesNew Product Sales
Formulations Business - Domestic
Value
(Rs. Mn.)Before 2006-07 5827 86%
2006-07 203 3%
2007-08 433 6%2008-09 104 2%
2009-10 98 1%
2010-11 149 2%New products launched inlast 5 yrs 987 14%
Grand Total 6814 100%
Year of Launch %
Contribution
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 19/48
Formulations Business - DomesticFuture Growth DriversFuture Growth Drivers
The company introduced 25 new Brands in the domestic market
during 2010-11Increased penetration through field force expansion.
Clinical research as a tool to launch innovative combination
formulations / NDDS.Strong Brand building with focused promotion.
In licensing/ out licensing to build business in the promoted therapy.
Portfolio optimization, strategies to identify need gaps to build, enter,maintain and exit approach.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 20/48
Domestic API Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 21/48
Domestic API Business
Sales Rs.Mn.Sales USD Mn.CAGR = 25%
API sales does not include captive consumption (FY 2010-11 Rs. 2271 Mn / USD 50 Mn.)
16
24
3132
2007-08 2008-09 2009-10 2010-11
741
1083
14161443
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 22/48
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 23/48
Exports to over 110 countries.
Recognised Trading House.Among Top 10 Pharma exporter from India.
54% sales from exports.
Field-force to promote brands in 40 countries of CIS,South East Asia, Middle East, Latin America andAfrica.
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 24/48
Marketing offices in Russia, Ukraine, Vietnam, Phillipines,Kenya, Columbia, Sri Lanka, Malaysia & Nigeria
(subsidiary company).Formulation Dossiers for Branded formulations registeredin 70 countries.
Forbes Asia has selected Ipca for 3 consecutive years–2003, 2004 ,2005 as one of the Best under a billioncompanies outside US.
Forbes Inc. selected Ipca as one of the ‘Best under aBillion Forbes Global’s 200 Best Small companies’ in 2007.
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 25/48
118
149
177
225
2007-08 2008-09 2009-10 2010-11
Sales Rs.Mn .
Sales USD Mn.
CAGR = 24%
10252
8061
5363
6804
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 26/48
Continent FormulationsBulk drugs/
IntermediatesTotal Cont.%
EUROPE 2800 1080 3880 38%
AFRICA 1716 329 2045 20%
ASIA 258 858 1116 11%
CIS 742 38 780 8%
AMERICAS 1159 951 2110 20%
AUSTRALASIA 242 79 321 3%
Total 6917 3335 10252 100%
International BusinessContinent-wise Exports 2010-11 (Rs(Rs MnMn ))
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 27/48
International Formulations Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 28/48
International Business - FormulationsSales Rs.Mn.Sales USD Mn.CAGR = 27%
75
96
107
152
2007-08 2008-09 2009-10 2010-11
6917
3420
4372
4892
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 29/48
International Business –
Branded Formulations
I t ti l B i
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 30/48
International Business –Branded Formulations
Sales Rs.Mn.Sales USD Mn.CAGR 12%
25
37
28
34
2007-08 2008-09 2009-10 2010-11
1558
1129
1684
1298
I t ti l B i
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 31/48
International Business –Branded Formulations
Future Growth DriversFuture Growth Drivers
Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments.
Geographical expansion in covered countries through additional fieldforce.
New geographies – South & Central American and West African countries.
Expansion in business lines - Institutions and Distributors.Introduction of new products. About 50 existing developed formulationsare identified for registration and launch across all continents.
The company’s wholly owned subsidiary in Mexico has started activities of
filing the formulation Dossiers for registration in the said countryThe company has started marketing its branded formulations inVenezuela, Colombia and Peru in the Latin American Market
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 32/48
International Generic Business
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 33/48
International Business –Generics (developed market)
1037South Africa
1414U.S. /Canada
527Australia /New Zealand
1044UnitedKingdom /EU
ProductsUnder
Registration
ProductsRegistered
CountrySales Rs.Mn.Sales USD Mn.CAGR 33%
2291
5359
2688
3594
50
59
79
118
2007-08 2008-09 2009-10 2010-11
5359
International Business
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 34/48
Future Growth DriversFuture Growth Drivers
International Business -Generic Formulations
Dossiers developed by company approved in UK are being takenfor MRP registration in other EU countries.
Own Dossier filings in Portugal.
Most formulations registered to be backed by own API.
Sale of Generic Dossiers with or without supply agreements.
Contract manufacturing arrangements.
Focus on Institutional business especially for Anti-malarials.
Approval for Anti-malarial finished dose combination formulation – Artemether + Lumefantrine under WHO’s PrequalificationProgramme. Ipca is the 4 th Company in the World to haveprequalification for this product.
International Business –
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 35/48
International Business Generic FormulationsFuture Growth Drivers – North America
Strategic tie up with Ranbaxy Inc. to market around 25 Genericformulations in U.S. In all the company has signed agreements
with 3 marketing partners for sale/ distribution of Genericformulations.
23 ANDAs filed of which 12 ANDAs are approved.
12 ANDA filings planned in FY 2011-12 and 10 to 12 ANDAstargetted for filing every year for next 3 years.
US Generic business commenced from September, 2008.
Many Generic products in pipeline for potential tie ups.
Exploring contract development and manufacturing opportunities.
Marketing arrangements signed for Canada.Generics export to Canada commenced in FY 2011-12.
International Business -
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 36/48
International Business Generic Formulations
Most ANDAs to be backed by own APIs.
Formulations manufacturing facility at SEZ Indorecommercialized and awaiting US-FDA inspection.
Future Growth DriversFuture Growth Drivers -- United StatesUnited States
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 37/48
International API Business
API B i I i l
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 38/48
API Business - International
Sales Rs.Mn.Sales USD Mn.CAGR 20%
43
53
7073
2007-08 2008-09 2009-10 2010-11
3335
1943
2432
3169
API DMF
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 39/48
API - DMFs
Sr. No. Name of the APIUS
FDAUK
MHRACanada
HPFB WHO PMDA Japan Australia EDQM
1 Atenolol a a a a a a
2 Artemether a a
3 Artesunate a a
4 Amodiaquine Hcl a a
5 Amlodipine Besylate a
6 Allopurinol a a a
7 Balsalazide Disodium Dihydrate a
8 Bendroflumethiazide a a
9 Bisoprolol Fumarate a
10 Carvedilol a a a
11 Cetrizine Dihydrochloride a a a
12 Chloroquine Phosphate a a a
13 Chloroquine Sulphate a
14 Chlorthalidone a a a
15 Cilostazolea
API DMF ( td )
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 40/48
API – DMFs (contd..)
Sr. No. Name of the APIUS
FDAUK
MHRACanada
HPFB WHO PMDA Japan Australia EDQM
16 Citalopram HBR a
17 Clopidogrel Bisulfate a
18 Etodolac a a
19 Fenofibrate a a
20 Fluconazole a a
21 Flumequine a
22 Furosemidea a a a a a
23 Glimeperide a a
24 Hydrochlorothiazide a a a a a a
25 Hydroxyzene Di Hcl a
26 Hydroxychloroquine Sulphate a a a a
27 Indapamide a a a
28 Isotretinoin a a
29 Losartan Potassium a a a a a
30 Lumefantrine a a
API DMF ( td )
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 41/48
API – DMFs (contd..)
Sr. No. Name of the APIUS
FDAUK
MHRACanada
HPFB WHO PMDA Japan Australia EDQM
31 Methylphenidate a a a
32 Mesalamine/ Mesalazine a a
33 Metformin HCL a a
34 Metoclopramide HCl a a a a a
35 Metoprolol Succinate a a
36 Metoprolol Tartrate a a a a a
37 Nabumetonea a
38 Ondansetron Hydrochloride a a a
39 Ondansetron Base a
40 Paroxetine Hcl a
41 Perindopril a
42 Probenecid a
43 Proguanil Hydrochloride a a
44 Propranolol HCl a a a a
45 Pyrantel Pamoate a a a a a
API DMFs (contd )
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 42/48
API – DMFs (contd..)
Sr. No. Name of the APIUS
FDAUK
MHRACanada
HPFB WHO PMDA Japan Australia EDQM
46 Pyrantel Tartrate a
47 Pyrimethamine Hcl a a
48 Quetiapine Fumarate a
49 Resperidone a a
50 Resindronate Sodium a
51 Sodium Alendronate a a
52 Sulfadoxine a a
53 Torsemidea
54 Tramadol Hydrochloride a a a
55 Trimethoprim a a a a a a
56 Triamterene a
57 Triclabendazole a
58 Valsartan a a
59 Warfarin Sodium Clathrate a a
60 Warfarin Sodium a a
61 Zoledronic Acid a
Total 58 13 16 4 9 9 34
API Business Future Growth Drivers
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 43/48
API Business – Future Growth Drivers
17 new APIs were commercialized in 2010-11
Aggressively pursuing MNC tie ups for supply agreements.
API source change / ANDA approvals of major US customers based on ourAPIs – Atenolol, Furosemide, Propranolol, Hydroxychloroquine Sulphate,Balsalazide, Hydrochlorthiazide to add nearly USD 10 mn. Business in next2 years.
Non-infringing process Patent filed for APIs – Losartan, Clopidogrel form 1,Metoprolol Succinate, Valsartan, Glimepride, Carvedilol, Isotretinoin and
Perindopril.Targeting 1 DMF filing per month.
Own API manufacturing to back formulations, especially for the Genericmarket.
Exploring strategic business relationship with smaller API manufacturersfor increasing product basket.
Management control of Tonira Pharma Ltd; an export oriented API companywith US-FDA approved manufacturing facility acquired in May 2008.
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 44/48
Research & Development(APIs & Formulations)
Research & Development
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 45/48
4%7132010-11
4%5022008-09
4%5732009-10
429
328
Rs. Mn.
4%2007-08
4%2006-07
% to SalesYear
Research & Development
R & D SpendingR & D Spending
Research & Development
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 46/48
Research & Development
New Division COVENANCE to undertake Contract Research andManufacturing Activities (CRAMS)
Current scientist manpower of over 350.
Research focus on developing APIs with non-infringing processand development of finished dosage forms.
Development of NDDS for Domestic and International market.
196 patent applications filed.
75 Patents granted (Indian – 58, US PTO - 11, EU- 6)
Research & Development
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 47/48
Working out strategy to start drug discovery program and to build infrastructure.
Bio-tech / fermentation research Laboratory established.
The company has subscribed to the capital of a newly incorporated subsidiarycompany Prayas Bio Lifescience Limited which will be engaged in Researchand Development of Biotech/Recombinant DNA Technology products.
2 in licensing arrangements with CSIR labs - NCE 97 / 78 CDRI compound nowentering into phase 1 Clinical trial.
Pursuing relationship and technical collaboration with CSIR Labs like CDRI,CIMAP & Universities like BITS Pilani. Working for more tie ups with academicinstitutions.
Undertaking contract research activities for APIs & Formulations forInternational clients.
Research & Development
Future StrategyFuture Strategy
8/3/2019 Ipca Corporate Presentation
http://slidepdf.com/reader/full/ipca-corporate-presentation 48/48
Thank YouThank You
No part of this Corporate Presentation may be re-produced, quoted or circulated without prior approvalof Ipca Laboratories Limited.
This presentation may include forward looking statements based on our current business expectations.Our actual results may differ from what is projected in this Corporate presentation. The viewers of thispresentation may use their own judgements and calculations before making any decision on any matterbased on the informations given herein.
The Company also disclaims any obligation to revise any of the information given in this presentation.